[(1S,2S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(1S,2S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate
• 化学式: C₂₄H₂₉ClO₄
• 分子量: 416.945
• InChiKey: UWFYSQMTEOIJJG-PMENGXGFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Combination, application thereof and treatment method
  申请人：KANGPU BIOPHARMACEUTICALS, LTD.

  公开号：US10933059B2

  公开（公告）日：2021-03-02

  Provided are a combination, an application thereof and a treatment method. The combination comprises one or more of a benzoheterocyclic compound of formula (I), a pharmaceutically acceptable salt, a solvate, a crystalline form, a cocrystal, a stereoisomer, an isotope compound, a metabolite and a prodrug thereof, and an androgen receptor pathway modulator and/or a hormone drug. The combination and treatment method may effectively inhibit the growth of prostate cancer cells.

  本文提供了一种组合物、其应用和治疗方法。该组合物包括一种或多种式（I）的苯并杂环化合物、药学上可接受的盐、溶液、结晶体、共晶体、立体异构体、同位素化合物、其代谢物和原药，以及雄激素受体通路调节剂和/或激素药物。这种组合和治疗方法可有效抑制前列腺癌细胞的生长。
• COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD
  申请人：KANGPU BIOPHARMACEUTICALS, LTD.

  公开号：US20190328722A1

  公开（公告）日：2019-10-31

  Provided are a combination, an application thereof and a treatment method. The combination comprises one or more of a benzoheterocyclic compound of formula (I), a pharmaceutically acceptable salt, a solvate, a crystalline form, a cocrystal, a stereoisomer, an isotope compound, a metabolite and a prodrug thereof, and an androgen receptor pathway modulator and/or a hormone drug. The combination and treatment method may effectively inhibit the growth of prostate cancer cells.
• METHOD FOR IMPROVING FETAL HEMOGLOBIN EXPRESSION
  申请人：EDIGENE INC.

  公开号：US20200339979A1

  公开（公告）日：2020-10-29

  Provided is a method for genetically editing an enhancer locus of hematopoietic stem cell BCL11A, comprising: disrupting the CTTCCT region of a BCL11A genome by gene editing technology. The genetically edited hematopoietic stem cells have normal cell functions and can significantly increase the expression of fetal hemoglobin, thereby being used for the treatment of β thalassemia and sickle cell anemia.
• METHOD FOR INCREASING FETAL HEMOGLOBIN EXPRESSION LEVEL
  申请人：EDIGENE INC.

  公开号：US20200384032A1

  公开（公告）日：2020-12-10

  Provided is a method for gene editing of an enhancer site of the BCL11A in hematopoietic stem cells. The genetically modified hematopoietic stem cells have the functions of normal cells, and can significantly increase the expression of fetal hemoglobin so as to be used in the treatment of β thalassemia and sickle cell anemia.
• Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof
  申请人：KANGPU BIOPHARMACEUTICALS, LTD.

  公开号：US20210113545A1

  公开（公告）日：2021-04-22

  Disclosed are a pharmaceutical composition comprising a benzoheterocyclic compound and androgen receptor pathway modulator and an application thereof. The pharmaceutical composition includes one or more of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a pro-drug thereof, and an androgen receptor pathway modulator. The pharmaceutical composition better inhibits prostate cancer cell growth.